RxDoctor Payments Data

Mariusz Milejczyk, MD

Internal Medicine · Libertyville, ILNPI 1467598235

Payments from drug & device makers

$1,220in general payments, 2019–2025

Across 34 payments — averaging $35.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$272
  • Boehringer Ingelheim$262
  • Astellas Pharma US Inc$198
  • Abbott$177
  • AstraZeneca$66
  • Actelion Pharmaceuticals US, Inc.$44
  • plus $201 from 7 others

What the payments were for

  • Food & beverage$1,02284%
  • Education$19816%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,220 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$164,840
Medicare patients
162
Services billed
8,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$71,740
TrulicityDulaglutide24$37,995
OzempicSemaglutide19$30,417
JardianceEmpagliflozin26$30,266
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$20,496
FarxigaDapagliflozin Propanediol14$13,528
Breo ElliptaFluticasone/Vilanterol15$9,745
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$5,231
LotrelAmlodipine Besylate/Benazepril23$4,904
Memantine Hcl84$4,279
Candesartan Cilexetil53$3,086
PremarinEstrogens, Conjugated11$2,517
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen131$2,167
Potassium Chloride113$2,110
Tamsulosin Hcl113$2,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$38$37,99524 claims
Novo NordiskOzempic$272$30,41719 claims
Boehringer IngelheimJardiance$262$30,26626 claims
AstraZenecaFarxiga$66$13,52814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Libertyville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →